Monaco Asset Management SAM raised its stake in Inogen, Inc. (NASDAQ:INGN - Free Report) by 104.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 76,500 shares of the medical technology company's stock after buying an additional 39,000 shares during the quarter. Monaco Asset Management SAM owned 0.32% of Inogen worth $702,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently added to or reduced their stakes in the company. Royce & Associates LP grew its holdings in shares of Inogen by 167.4% during the third quarter. Royce & Associates LP now owns 51,891 shares of the medical technology company's stock worth $503,000 after buying an additional 32,482 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Inogen by 312.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company's stock worth $1,694,000 after acquiring an additional 132,287 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Inogen by 13.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company's stock worth $409,000 after acquiring an additional 5,131 shares during the period. Verition Fund Management LLC acquired a new stake in Inogen during the 3rd quarter worth approximately $106,000. Finally, Paloma Partners Management Co acquired a new stake in Inogen during the 3rd quarter worth approximately $126,000. Institutional investors and hedge funds own 89.94% of the company's stock.
Inogen Trading Down 2.3 %
NASDAQ INGN traded down $0.17 during midday trading on Tuesday, hitting $7.33. The company had a trading volume of 213,550 shares, compared to its average volume of 234,424. The company has a market capitalization of $194.46 million, a PE ratio of -3.26 and a beta of 1.15. The firm has a 50-day moving average price of $9.92 and a 200-day moving average price of $9.80. Inogen, Inc. has a twelve month low of $6.14 and a twelve month high of $13.33.
Analysts Set New Price Targets
INGN has been the subject of several research reports. Needham & Company LLC reissued a "hold" rating on shares of Inogen in a report on Wednesday, February 26th. StockNews.com cut Inogen from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th.
Check Out Our Latest Research Report on Inogen
About Inogen
(
Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
